Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma

ITT

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id: NCT00049036
trial label: Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00049036
outcome key
om-0000
source section id
NCT00049036-om-0000
source outcome index
0
endpoint
Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment
endpoint definition
Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma
time origin
60 days
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
ITT
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00049036
outcome key
om-0000
arm key
OG000
arm label
EPOCH + Concurrent Rituximab
regimen
Patients receive rituximab IV over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
analyzed count
51
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00049036-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00049036
outcome key
om-0000
arm key
OG001
arm label
EPOCH Followed by Rituximab
regimen
Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
analyzed count
55
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00049036-om-0000#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00049036
harm key
EG000
source section id
NCT00049036-ae
event group key
EG000
event group label
EPOCH + Concurrent Rituximab
serious affected
28
serious at risk
51
other affected
50
other at risk
51
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-aggressive-b-cell-non-hodgkin-lymphoma
nct id
NCT00049036
harm key
EG001
source section id
NCT00049036-ae
event group key
EG001
event group label
EPOCH Followed by Rituximab
serious affected
27
serious at risk
55
other affected
51
other at risk
55
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice